Europe Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User

List of Tables

The Europe pharmacokinetics services market was valued at US$ 222.16 million in 2023 and is expected to reach US$ 387.38 million by 2031; it is estimated to register a CAGR of 7.2% from 2023 to 2031.

Outsourcing of Pharmacokinetics Services to CROs Drives Europe Pharmacokinetics Services Market

Outsourcing pharmacokinetics services to contract research organizations (CROs) offers several advantages to drug manufacturers and sponsors. They can operate cost-effectively by opting for these services. Moreover, they can focus on working flexibly and bringing scalability to their core operations, alongside achieving fast turnaround time. Outsourcing helps pharmaceutical companies to focus on product commercialization while implementing measures for capacity building, cost reduction, and data management. The drug discovery process is complex, and any error or false result can lead to significant costs and delay the process. CROs employ experienced scientists and researchers who hold expertise in pharmacokinetics and other fields. Thus, they provide pharma companies with access to their expertise, thereby eliminating the need to invest in hiring such skilled workforces or providing extra training to build them. Therefore, small companies with promising drug candidates but limited resources and large companies involved in diversifying their operations are opting for clinical research services provided by well-organized CROs, which bolsters the Europe pharmacokinetics services market.

Europe Pharmacokinetics Services Market Overview

The Europe pharmacokinetics services market is segmented into Germany, France, the UK, Spain, Italy, and the Rest of Europe. Countries such as Germany and Italy are expected to account significant contributors share of the market in the region, and countries such as France, the UK, and Spain are likely to have growth opportunities for pharmacokinetics services. The European pharmacokinetics services market is expected to grow in the coming years with the rising number of clinical trials for new drug development, and the increasing adoption of in-vivo and in-vitro models for understanding pharmacokinetics variability.

Europe Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)

Europe Pharmacokinetics Services Market Segmentation

The Europe pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.

Based on drug type, the Europe pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.

In terms of service type, the Europe pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.

By therapeutic application, the Europe pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.

By end user, the Europe pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.

By country, the Europe pharmacokinetics services market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. France dominated the Europe pharmacokinetics services market share in 2023.

Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the Europe pharmacokinetics services market.

Product Code: BMIRE00030902

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Pharmacokinetics Services Market - Key Market Dynamics

4.1 Market Drivers
- 4.1.1 Rising Prevalence of Chronic and Infectious Diseases
- 4.1.2 Expanding Range of Application of Pharmacokinetic Studies
- 4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
- 4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
- 4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
- 4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:

5. Pharmacokinetics Services Market - Europe Analysis

5.1 Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031

6. Europe Pharmacokinetics Services Market Analysis - by Drug Type

6.1 Overview
6.2 Small Molecule
- 6.2.1 Overview
- 6.2.2 Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
- 6.3.1 Overview
- 6.3.2 Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
- 6.4.1 Overview
- 6.4.2 Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

7. Europe Pharmacokinetics Services Market Analysis - by Service Type

7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
- 7.2.1 Overview
- 7.2.2 Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
- 7.3.1 Overview
- 7.3.2 PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
- 7.4.1 Overview
- 7.4.2 Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
- 7.5.1 Overview
- 7.5.2 Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

8. Europe Pharmacokinetics Services Market Analysis - by Therapeutic Application

8.1 Oncology
- 8.1.1 Overview
- 8.1.2 Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
- 8.2.1 Overview
- 8.2.2 Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
- 8.3.1 Overview
- 8.3.2 Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
- 8.4.1 Overview
- 8.4.2 Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
- 8.5.1 Overview
- 8.5.2 Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
- 8.6.1 Overview
- 8.6.2 Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
- 8.7.1 Overview
- 8.7.2 Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

9. Europe Pharmacokinetics Services Market Analysis - by End User

9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
- 9.2.1 Overview
- 9.2.2 Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)

10. Europe Pharmacokinetics Services Market - Country Analysis

10.1 Europe
- 10.1.1 Europe Pharmacokinetics Services Market Breakdown by Countries, 2023 and 2031 (%)
  - 10.1.1.1 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.1.1 Overview
    - 10.1.1.1.2 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.1.3 Germany: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
    - 10.1.1.1.4 Germany: Europe Pharmacokinetics Services Market Breakdown, by Service Type
    - 10.1.1.1.5 Germany: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 10.1.1.1.6 Germany: Europe Pharmacokinetics Services Market Breakdown, by End User
  - 10.1.1.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.2.1 Overview
    - 10.1.1.2.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.2.3 France: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
    - 10.1.1.2.4 France: Europe Pharmacokinetics Services Market Breakdown, by Service Type
    - 10.1.1.2.5 France: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 10.1.1.2.6 France: Europe Pharmacokinetics Services Market Breakdown, by End User
  - 10.1.1.3 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.3.1 Overview
    - 10.1.1.3.2 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.3.3 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
    - 10.1.1.3.4 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Service Type
    - 10.1.1.3.5 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 10.1.1.3.6 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by End User
  - 10.1.1.4 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.4.1 Overview
    - 10.1.1.4.2 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.4.3 Italy: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
    - 10.1.1.4.4 Italy: Europe Pharmacokinetics Services Market Breakdown, by Service Type
    - 10.1.1.4.5 Italy: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 10.1.1.4.6 Italy: Europe Pharmacokinetics Services Market Breakdown, by End User
  - 10.1.1.5 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.5.1 Overview
    - 10.1.1.5.2 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.5.3 Spain: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
    - 10.1.1.5.4 Spain: Europe Pharmacokinetics Services Market Breakdown, by Service Type
    - 10.1.1.5.5 Spain: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 10.1.1.5.6 Spain: Europe Pharmacokinetics Services Market Breakdown, by End User
  - 10.1.1.6 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.6.1 Overview
    - 10.1.1.6.2 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
    - 10.1.1.6.3 Rest of Europe Pharmacokinetics Services Market Breakdown, by Drug Type
    - 10.1.1.6.4 Rest of Europe Pharmacokinetics Services Market Breakdown, by Service Type
    - 10.1.1.6.5 Rest of Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
    - 10.1.1.6.6 Rest of Europe Pharmacokinetics Services Market Breakdown, by End User

11. Company Profile

11.1 Charles River Laboratories International Inc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Eurofins Scientific SE
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Evotec SE
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Certara Inc.
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
11.5 Parexel International Corp
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Thermo Fisher Scientific Inc.
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Allucent
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 PACIFIC BIOLABS
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 SGS SA
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market